CeriBell, Inc. (NASDAQ:CBLL) Given Average Rating of “Moderate Buy” by Brokerages

CeriBell, Inc. (NASDAQ:CBLL) has received an average rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $22.20.

CBLL has been the topic of a number of research analyst reports. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 27th. Canaccord Genuity Group lowered their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th.

CeriBell Stock Performance

Shares of NASDAQ:CBLL opened at $18.47 on Wednesday. The stock has a 50 day moving average of $18.98 and a 200 day moving average of $19.70. The company has a current ratio of 10.44, a quick ratio of 10.01 and a debt-to-equity ratio of 0.14. CeriBell has a 12-month low of $10.85 and a 12-month high of $24.33. The company has a market cap of $700.75 million, a PE ratio of -11.33 and a beta of 0.85.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The business had revenue of $26.49 million during the quarter, compared to analysts’ expectations of $26.09 million. As a group, equities research analysts expect that CeriBell will post -1.69 EPS for the current year.

Insider Buying and Selling

In related news, CTO Raymond Woo sold 11,112 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $18.56, for a total value of $206,238.72. Following the transaction, the chief technology officer directly owned 166,912 shares of the company’s stock, valued at approximately $3,097,886.72. The trade was a 6.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Xingjuan Chao sold 39,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $18.33, for a total value of $714,870.00. Following the completion of the transaction, the chief executive officer directly owned 816,317 shares in the company, valued at approximately $14,963,090.61. This represents a 4.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 151,826 shares of company stock worth $2,877,244. 20.10% of the stock is owned by insiders.

Institutional Trading of CeriBell

Several hedge funds have recently modified their holdings of CBLL. JPMorgan Chase & Co. raised its holdings in shares of CeriBell by 6,424.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock worth $7,117,000 after acquiring an additional 374,179 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of CeriBell by 109.9% during the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock worth $614,000 after acquiring an additional 17,177 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of CeriBell by 148.6% during the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock worth $163,000 after acquiring an additional 5,200 shares in the last quarter. Quantbot Technologies LP raised its holdings in shares of CeriBell by 70.3% during the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock worth $290,000 after acquiring an additional 6,401 shares in the last quarter. Finally, Invesco Ltd. purchased a new stake in shares of CeriBell during the 2nd quarter worth approximately $197,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.